- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07731529
Vivifrail Exercise Program in Nonagenarians: Effects on Function, Muscle, and Cognition (Vivifrail)
Effects of a Multicomponent Exercise Program Based on the Vivifrail Protocol on Functional Capacity, Muscle Morphology, and Cognition in Nonagenarians: A Randomized Clinical Trial
연구 개요
상세 설명
This is a three-arm, parallel-group randomized controlled trial evaluating a home-based multicomponent exercise program based on the Vivifrail protocol in community-dwelling nonagenarians (aged 90 years or older). A total of 54 participants (18 per group) will be randomly allocated to one of three groups: G1, performing the Vivifrail program at least twice a week; G2, performing it at least three times a week; or a control group (GC) maintaining usual activities.
Randomization will be performed using Randomizer software (www.randomizer.org) by an independent researcher not involved in the assessments. Allocation is stratified by sex and by baseline functional level, defined by collapsing the six Vivifrail functional categories into two groups (lower function: Types A, B, and B+; higher function: Types C, C+, and D), to ensure balanced distribution of baseline physical function across the three groups. Each participant is still assigned the individualized Vivifrail training passport corresponding to their specific functional category. Given the autonomous, home-based nature of the intervention, participants and interventionists cannot be blinded; however, outcome assessors remain blinded to group allocation throughout the study.
Assessments occur at three timepoints: baseline (T0), 12 weeks (T1), and 24 weeks (T2). The 24-week intervention is individualized according to each participant's functional profile, determined by the Short Physical Performance Battery (SPPB) and the corresponding Vivifrail training passport.
The primary outcome is physical function measured by the total SPPB score (0-12). Secondary outcomes include mobility (Timed Up and Go and cognitive dual-task cost), handgrip strength, lower-limb power (five-times sit-to-stand with linear encoder), gait speed, balance, muscle morphology of the vastus lateralis (ultrasound), cognition (Mini-Mental State Examination), and change in Vivifrail functional category. Data will be analyzed by intention to treat using generalized estimating equations (GEE), examining the group-by-time interaction.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 90035-903
- Hospital de Clínicas de Porto Alegre (HCPA) - Geriatrics outpatient clinic
-
Porto Alegre, Rio Grande do Sul, 브라질, 90690-200
- Escola de Educação Física, Fisioterapia e Dança (ESEFID/UFRGS) - and participants' homes
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Aged 90 years or older
- Living in the community (own or family home)
- Able to walk independently or with a walking aid (cane or walker), without third-party assistance
- Minimum cognitive capacity to understand and perform the exercises (MMSE, education-adjusted cutoffs)
- Adequate home conditions to perform the program
- Availability of a family member or caregiver to support the sessions
- Signed informed consent (with legal guardian assistance when needed)
Exclusion Criteria:
- - Total inability to walk or permanent bedridden condition
- Severe cognitive impairment preventing safe understanding and execution of exercises
- Severe orthopedic, neurological, or rheumatological conditions preventing exercise
- Concurrent participation in another structured exercise program
- Anticipated unavailability (relocation, planned hospitalization, or institutionalization) during the intervention
- Refusal to sign informed consent or absence of a legal guardian when required
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Vivifrail - 2 sessions/week (G1)
Home-based Vivifrail multicomponent exercise program performed at least twice a week for 24 weeks, individualized by functional profile (SPPB and Vivifrail passport).
|
Individualized multicomponent home-based training (strength/power, balance, gait, and flexibility) prescribed according to the participant's Vivifrail functional profile.
|
|
실험적: Vivifrail - 3 sessions/week (G2)
Home-based Vivifrail multicomponent exercise program performed at least three times a week for 24 weeks, individualized by functional profile.
|
Individualized multicomponent home-based training (strength/power, balance, gait, and flexibility) prescribed according to the participant's Vivifrail functional profile.
|
|
간섭 없음: Control (GC)
Participants maintain usual activities without a structured exercise program during the 24-week period.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in physical function measured by the Short Physical Performance Battery (SPPB) total score
기간: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Total SPPB score ranging from 0 to 12 points (higher scores indicate better lower-extremity physical function), combining balance, gait speed, and chair-stand tests.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mobility - Timed Up and Go (TUG)
기간: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
ime in seconds to rise, walk 3 meters, turn, return, and sit.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Mobility under dual task - Cognitive TUG and dual-task cost (DTC%) ·
기간: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
TUG performed with a concurrent cognitive task; dual-task cost calculated as percentage change relative to single-task TUG.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Handgrip strength
기간: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
Maximal isometric handgrip strength in kilograms, measured with a Jamar dynamometer.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Lower-limb muscle power - Five-times sit-to-stand
기간: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
ime in seconds and estimated lower-limb power measured during the five-times sit-to-stand test using a linear encoder.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Gait speed
기간: aseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
Usual gait speed in meters per second.
|
aseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Balance
기간: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
Static balance assessed by the SPPB balance component (side-by-side, semi-tandem, and tandem stands).
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)).
|
|
Change in Vastus Lateralis Muscle Thickness
기간: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Vastus lateralis muscle thickness measured by B-mode ultrasound, defined as the distance between the adipose-muscle and muscle-bone interfaces, analyzed in ImageJ by a single trained, blinded assessor.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Change in Vastus Lateralis Echo Intensity (Muscle Quality)
기간: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Muscle quality assessed by echo intensity on B-mode ultrasound, expressed in arbitrary units (grayscale, 0-255) via manual region-of-interest analysis in ImageJ, excluding fascia and bone.
Higher echo intensity indicates greater intramuscular fat/fibrous infiltration, i.e., poorer muscle quality.
Single assessor blinded to group allocation.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Cognition - Mini-Mental State Examination (MMSE)
기간: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Global cognitive function measured by the MMSE, using education-adjusted cutoffs.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
|
Change in Vivifrail functional category
기간: Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
Transition across Vivifrail functional categories (Types A, B, B+, C, C+, D) over the intervention period.
|
Baseline (T0), 12 weeks (T1), and 24 weeks (T2)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 79748517.5.0000.5347
- U1111-1343-8083 (기타 식별자: WHO Universal Trial Number (UTN))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .